Ancor joined Sentinel Capital and Yukon Capital to complete the transaction.
Ancor Capital Partners managing partner J Randall Keene said WellSpring represents the 15th acquisition of a healthcare company for Ancor and combines their experience in contract manufacturing, pharmaceutical sales and OTC products.
"We are very pleased to have teamed with Sentinel and Yukon on this acquisition," Keene added.
WellSpring Pharmaceutical Chief Financial Officer and Chief Operating Officer Wendy Shusko said under Ancor and Sentinel, the company can achieve the aggressive growth opportunities in the market.